{"gene":"E2F5","run_date":"2026-06-09T23:54:42","timeline":{"discoveries":[{"year":1995,"finding":"E2F-5 protein was cloned and shown to heterodimerize with DP-1, enabling high-affinity binding to E2F DNA recognition sequences. E2F-5 preferentially interacts with p130 (not pRb) in a yeast two-hybrid assay, in contrast to E2F-1, -2, and -3 which bind pRb.","method":"Yeast two-hybrid, co-immunoprecipitation, DNA binding assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — independently replicated across multiple labs in the same year (PMID 7892279, 7760804, 7542760) using yeast two-hybrid, in vitro binding, and cell-based assays","pmids":["7892279","7760804","7542760"],"is_preprint":false},{"year":1995,"finding":"E2F-5 contains a potent transcriptional activation domain in its C-terminal region that functions in both yeast and mammalian cells and is specifically inactivated upon pocket protein binding. E2F-5 and E2F-4 define a subfamily structurally and functionally distinct from E2F-1, -2, and -3.","method":"Reporter gene assays in yeast and mammalian cells, deletion mutagenesis, two-hybrid assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — functional domain mapping with mutagenesis confirmed in both yeast and mammalian systems, replicated across labs","pmids":["7542760","9464260"],"is_preprint":false},{"year":1995,"finding":"Under physiological conditions, E2F-5 interacts preferentially with p130 (not pRb or p107) as demonstrated by specific antiserum immunoprecipitation from cell extracts.","method":"Co-immunoprecipitation with specific E2F-5 antiserum","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with specific antiserum, replicated by multiple independent labs","pmids":["7760804"],"is_preprint":false},{"year":1998,"finding":"E2F-5 knockout mice develop nonobstructive hydrocephalus with excessive CSF production from the choroid plexus. E2F-5 CNS expression is largely confined to the choroid plexus, and its loss affects secretory behavior of this differentiated neural tissue without perturbing cell cycle kinetics in knockout fibroblasts.","method":"Gene targeting (homozygous knockout mice), histology, electron microscopy, in situ hybridization","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO mouse model with specific phenotypic readout and localization data, single rigorous study with multiple orthogonal methods","pmids":["9553039"],"is_preprint":false},{"year":2000,"finding":"Simultaneous inactivation of E2F4 and E2F5 in mice results in neonatal lethality. Embryonic fibroblasts from E2F4/E2F5 double-knockout mice fail to arrest in G1 in response to p16INK4a, demonstrating that E2F4 and E2F5 are dispensable for cell cycle progression but necessary for pocket protein-mediated G1 arrest.","method":"Double-knockout mouse genetics, cell cycle analysis, p16INK4a-induced arrest assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double-knockout mice and defined cellular phenotype, single rigorous study with multiple functional readouts","pmids":["11030352"],"is_preprint":false},{"year":2000,"finding":"E2F5 gene (mapped to 8q21.1-21.3) can promote morphologically transformed foci in primary baby rat kidney cells when overexpressed with DP1 and activated RAS, demonstrating oncogenic cooperation analogous to MYC-type cooperating oncogenes.","method":"Focus formation assay in primary BRK cells, gene mapping, copy number analysis in breast tumors","journal":"Genes, chromosomes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional transformation assay with defined partners, single lab, complemented by chromosomal mapping","pmids":["10738311"],"is_preprint":false},{"year":2002,"finding":"E2F-5 nuclear import requires only the first N-terminal 56 amino acids and is independent of DP or pRB family proteins. E2F-5 is exported from the nucleus via CRM1-mediated (leptomycin B-sensitive) transport through a region corresponding to amino acid residues 130-154, which excludes the DNA- and p130-binding domains. Keratinocyte differentiation drives E2F-5 nuclear translocation.","method":"In vitro nuclear import assays in digitonin-permeabilized cells, leptomycin B inhibition, deletion mutant analysis, immunofluorescence in keratinocytes","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro nuclear import reconstitution combined with domain mutagenesis and pharmacological inhibition, single lab with multiple orthogonal approaches","pmids":["12089160"],"is_preprint":false},{"year":2005,"finding":"E2F5 protein localizes to the nucleus in immature/proliferating choroid plexus epithelial cells and shifts to the cytoplasm as cells mature (change from pseudostratified to cuboidal epithelium), a change that does not correlate with PCNA-positive proliferating cells but parallels morphological maturation.","method":"Immunohistochemistry, in situ hybridization, PCNA co-staining in mouse and human developing choroid plexus","journal":"The International journal of developmental biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization by IHC across developmental stages in two species, but no functional manipulation","pmids":["16172982"],"is_preprint":false},{"year":2007,"finding":"E2F5 and LEK1 translocate to the nucleus as an early event in Raf/MEK/ERK-driven myoblast quiescence. Disruption of MEK1 activity prevents ERK1/2 phosphorylation and nuclear translocation of E2F5 and LEK1. E2F5 and LEK1 are found in nuclei of non-dividing satellite cells and myonuclei in vivo.","method":"Proteomics (2D-gel + MS), immunofluorescence, pharmacological MEK inhibition, in vivo satellite cell staining","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — proteomic identification plus pharmacological epistasis and in vivo correlation, single lab","pmids":["17295207"],"is_preprint":false},{"year":2008,"finding":"Overexpression of E2F5 alone is not sufficient to inhibit E2F1- or E2F3a-induced cell cycle reentry in lens fiber cells in vivo. However, coexpression of E2F5 together with p130 inhibits activator E2F-mediated cell proliferation, confirming that p130 is required for E2F5's repressive activity.","method":"Transgenic mouse crossing experiments, BrdU incorporation, immunohistochemistry, in situ hybridization","journal":"Molecular vision","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo with multiple transgenic combinations and functional proliferation readout, single lab with rigorous controls","pmids":["18385796"],"is_preprint":false},{"year":2010,"finding":"E2F5 acts as a direct transcriptional activator (not repressor) of HPV18 E6/E7 oncogenes by binding E2F sites specific to HPV18 in HeLa cells. Sequential silencing of E2F family members identified E2F5 as the activator. E2F5 also positively regulates S-phase entry specifically in HPV18-expressing cells.","method":"Sequential siRNA silencing of E2F family members, luciferase reporter assays, cell cycle analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — sequential silencing with reporter validation, functional cell cycle assay, single lab","pmids":["20639900"],"is_preprint":false},{"year":2011,"finding":"miR-128-2, induced by mutant p53 (p53R175H), post-transcriptionally targets E2F5 and abrogates its repressive activity on p21(waf1) transcription. Loss of E2F5 repression leads to cytoplasmic p21 accumulation which prevents pro-caspase-3 cleavage, contributing to chemoresistance in non-small-cell lung cancer.","method":"Reporter assays, Western blot, miRNA overexpression/knockdown, ChIP for mutant p53 on ARPP21 promoter","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — miRNA target validation plus mechanistic pathway linking E2F5 to p21 transcription and apoptosis, single lab with multiple orthogonal methods","pmids":["22193543"],"is_preprint":false},{"year":2015,"finding":"E2F5 is a direct target of miR-98 in human myoblasts, and E2F5 binds to the promoters of the differentiation inhibitors ID1 and HMOX1, repressing their expression. Simultaneous knockdown of E2F5 and miR-98 restores normal skeletal muscle differentiation, placing E2F5 downstream of miR-98 in regulating myogenesis.","method":"Transcriptomic analysis, direct miRNA target validation, ChIP on ID1 and HMOX1 promoters, genetic epistasis by double knockdown","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct promoter binding plus genetic epistasis with rescue experiment, single lab with multiple orthogonal methods","pmids":["25422988"],"is_preprint":false},{"year":2016,"finding":"E2F5 overexpression is associated with elevated p38 phosphorylation and SMAD3 phosphorylation at the linker region (Ser-208, pSMAD3L) in prostate cancer. Downregulation of E2F5 and p38 by siRNA in PC3 cells reduces SMAD3 phosphorylation and causes G1 cell cycle arrest, defining an E2F5/p38/SMAD3 axis in prostate cancer proliferation.","method":"siRNA knockdown, Western blot, immunostaining, qRT-PCR, cell cycle analysis","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — siRNA epistasis with molecular readouts in cell line and patient tissue, single lab","pmids":["26919443"],"is_preprint":false},{"year":2016,"finding":"E2f4 and E2f5 are required for the development of multiciliated cells and absorptive cells in efferent ducts; conditional deletion of E2f4 in Vil-cre;E2f5+/- males eliminates multiciliated cells and reduces aquaporin1 and clusterin expression in efferent ducts, causing male sterility due to defective fluid absorption.","method":"Conditional knockout mouse genetics (Vil-cre;E2f4f/f;E2f5+/-), histology, immunohistochemistry","journal":"Cell cycle (Georgetown, Tex.)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean conditional KO with specific molecular and cellular phenotype, single lab with multiple orthogonal readouts","pmids":["26825228"],"is_preprint":false},{"year":2018,"finding":"In zebrafish, E2f5 is essential for MCC development in kidney tubules, while E2f4 is dispensable. Using double mutant combinations, E2f5 has a more prominent role than E2f4 in zebrafish MCC development, contrasting with the mouse where E2f4 appears dominant.","method":"Zebrafish mutant genetics, double mutant analysis, whole mount immunostaining","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with multiple mutant combinations in defined tissue, replicated findings across groups","pmids":["30218642"],"is_preprint":false},{"year":2019,"finding":"MYCN directly binds an E-Box motif in the E2F5 gene promoter to induce its transcription, as confirmed by ChIP and reporter assays. E2F5 knockdown in MYCN-amplified neuroblastoma cells inhibits proliferation and reduces CDK2 and CDK6 expression.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, siRNA knockdown, Western blot","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay establishing direct transcriptional regulation, single lab","pmids":["30765227"],"is_preprint":false},{"year":2019,"finding":"E2F5 can bind to the promoter of lncPCAT1 in periodontal ligament stem cells, forming a feed-forward regulatory network in which E2F5 drives lncPCAT1 expression which in turn sponges miR-106a-5p to upregulate BMP2, promoting osteogenic differentiation.","method":"ChIP assay, luciferase reporter assay, miRNA sponge validation, osteogenic differentiation assays in vitro and in vivo","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay with functional osteogenic differentiation readout, single lab","pmids":["30997692"],"is_preprint":false},{"year":2020,"finding":"E2F5 promotes prostate cancer cell migration and invasion by acting as a transcriptional activator/repressor at TFPI2, MMP-2, and MMP-9 promoters. ChIP with anti-E2F5 IgG confirmed E2F5 recruitment to these promoters; E2F5 represses TFPI2 and activates MMP-2/MMP-9, increasing gelatinolytic activity.","method":"RNAi knockdown, pathway-focused gene expression profiling, ChIP-qPCR, site-directed mutagenesis, dual-luciferase assay, Proteome Profiler array, gelatin zymography, co-immunoprecipitation in tissue","journal":"Carcinogenesis","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP with mutagenesis and multiple orthogonal methods (reporter, proteome profiler, zymography, Co-IP in tissue), single lab","pmids":["32386317"],"is_preprint":false},{"year":2020,"finding":"E2F5 knockout in zebrafish causes spermatogenesis arrest at the zygotene stage due to homologous recombination defects and germ cell apoptosis. E2F5 directly binds the promoter of dmc1 (meiotic recombination protein) to promote its transcription; overexpression of dmc1 rescues fertilization in e2f5 mutant males. E2f5 also activates the Notch pathway gene jagged2b to inhibit MCC fate acquisition by neighboring principal cells.","method":"Zebrafish mutant genetics, transcriptome analysis, ChIP on dmc1 promoter, dmc1 rescue by overexpression, double mutant analysis (e2f5;tp53)","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP demonstrating direct promoter binding plus genetic rescue with dmc1, multiple double-mutant combinations and transcriptomics, single lab with comprehensive orthogonal methods","pmids":["32196499"],"is_preprint":false},{"year":2020,"finding":"E2F5 knockdown in wild-type TP53-bearing breast cancer cells (MCF7) induces cell death through upregulation of TP53-target pro-apoptotic genes (BAX, NOXA, PUMA). This effect is abrogated by TP53 silencing and is not observed in mutant TP53 cells, indicating E2F5 suppresses TP53-mediated apoptosis in a TP53-dependent manner.","method":"siRNA knockdown, real-time RT-qPCR, TP53 co-silencing epistasis experiment, cell death assays","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (E2F5 KD + TP53 KD) with defined molecular readouts, single lab","pmids":["33000282"],"is_preprint":false},{"year":2021,"finding":"CDK13 physically interacts with E2F5 (confirmed by Co-IP coupled to mass spectrometry) and this interaction strengthens the pro-proliferation effect of CDK13. Transcriptional activation of CDK13 promotes E2F5 protein expression by facilitating circCDK13 biogenesis, which sponges miR-212-5p/449a to relieve repression of E2F5, forming a positive feedback loop.","method":"Co-immunoprecipitation plus mass spectrometry, CRISPR-Cas9 endogenous activation, loss/gain-of-function assays in vitro and in vivo","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP/MS identifying physical interaction, CRISPR-based endogenous activation, single lab","pmids":["33390186"],"is_preprint":false},{"year":2021,"finding":"An E2F5-TFDP1-BRG1 complex binds the MYCN promoter in hepatocytes to drive MYCN transcription during liver regeneration. BRG1 is recruited by E2F5/TFDP1 and promotes histone H3 acetylation and H3K4 trimethylation at the MYCN promoter, facilitating RNA polymerase II binding.","method":"RNA interference validation of E2F5 and TFDP1, ChIP for BRG1/E2F5/TFDP1 at MYCN promoter, histone modification analysis, MYCN overexpression rescue in BRG1-null hepatocytes","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP establishing complex recruitment with histone modification readout and genetic rescue, single lab","pmids":["34746136"],"is_preprint":false},{"year":2021,"finding":"E2F5 directly upregulates UBE2T transcription in gastric cancer cells, as confirmed by correlation analysis and transcriptional regulation assays. E2F5 depletion inhibits proliferation and invasion, and UBE2T overexpression reverses these effects.","method":"siRNA knockdown, GSEA, correlation analysis, transcription regulation assay, rescue by UBE2T overexpression","journal":"Digestive and liver disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — transcriptional regulation assay without detailed mechanistic characterization (no ChIP reported in abstract), single lab","pmids":["34583905"],"is_preprint":false},{"year":2022,"finding":"METTL3 promotes E2F5 mRNA stability through m6A methylation of E2F5 transcripts, as demonstrated by MeRIP assay. Silencing METTL3 decreases E2F5 expression and inhibits pancreatic cancer cell viability; overexpression of E2F5 reverses the anti-tumor effects of METTL3 knockdown.","method":"MeRIP assay (m6A methylation), RT-qPCR, Western blot, CCK-8, rescue experiments","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeRIP directly measuring m6A modification of E2F5 mRNA plus functional epistasis rescue, single lab","pmids":["35985439"],"is_preprint":false},{"year":2024,"finding":"IMP3 (RNA-binding protein) binds E2F5 mRNA directly (confirmed by RNA immunoprecipitation), and silencing IMP3 shortens E2F5 mRNA half-life and reduces E2F5 protein expression, thereby inhibiting OSCC cell proliferation.","method":"RNA immunoprecipitation (RIP), mRNA stability assay, siRNA knockdown, in vivo xenograft","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP establishing direct mRNA-protein interaction with functional mRNA stability measurement, single lab","pmids":["38271139"],"is_preprint":false},{"year":2024,"finding":"Mammary-specific conditional knockout of E2F5 results in delayed alveolar expansion during early pregnancy with reduced E2F target gene expression. E2F5 deletion leads to enrichment of luminal progenitor populations at the expense of differentiated alveolar cells, with depletion of the repressive H3K27me3 mark at luminal progenitor-associated genes. After prolonged latency, E2F5 conditional knockout mice develop highly metastatic mammary tumors with altered Cyclin D1 levels.","method":"scRNAseq, mammary-specific conditional knockout, chromatin profiling (H3K27me3), RNAseq, whole genome sequencing, transplantation assay, Western blot","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with chromatin profiling, transcriptomics, and multiple functional readouts, single rigorous study with comprehensive orthogonal methods","pmids":["39341991"],"is_preprint":false},{"year":2024,"finding":"E2F5 loss leads to delayed alveolar expansion during early pregnancy with reduced proliferation (decreased canonical E2F target gene expression) and a block in luminal progenitor differentiation into alveolar precursors, associated with depletion of H3K27me3 at luminal progenitor genes. E2F5 chromatin binding increases during early pregnancy.","method":"Mammary epithelial-specific conditional knockout, scRNAseq, chromatin profiling, RNAseq","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — preprint with conditional KO and chromatin profiling, not yet peer-reviewed, single lab","pmids":[],"is_preprint":true},{"year":2025,"finding":"E2F5 promotes VSMC phenotypic switching in diabetic atherosclerosis through activation of the Wnt/β-catenin pathway. E2F5 knockdown inhibits phenotypic transformation of VSMCs, and CyclinE overexpression reverses this inhibition. BML-284 (Wnt activator) attenuates the inhibitory effect of E2F5 silencing.","method":"siRNA knockdown, CyclinE overexpression rescue, pharmacological Wnt pathway modulation (BML-284), in vivo DAS mouse model, Western blot","journal":"Diabetes & metabolism journal","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — pharmacological epistasis plus genetic rescue in vitro and in vivo, single lab","pmids":["40890020"],"is_preprint":false}],"current_model":"E2F5 is a transcriptional regulator that forms heterodimers with DP proteins and associates preferentially with the pocket protein p130 (not pRb) to mediate G1 arrest; it shuttles between cytoplasm and nucleus via CRM1-mediated export and an N-terminal import signal, with nuclear entry driven by differentiation cues; while classically considered a repressor, E2F5 can function as a transcriptional activator (e.g., at MMP-2/MMP-9, dmc1, MYCN, and HPV18 E6/E7 promoters) through context-dependent complex formation (e.g., E2F5-TFDP1-BRG1); its stability is regulated post-transcriptionally by m6A methylation via METTL3 and by the RNA-binding protein IMP3; in vivo loss-of-function studies reveal non-proliferative roles in choroid plexus secretory function, multiciliated cell differentiation, spermatogenesis (via dmc1 transactivation), and mammary alveolar development, while acting as a tumor suppressor in mammary tissue whose loss eventually drives metastatic tumors."},"narrative":{"mechanistic_narrative":"E2F5 is a DP-heterodimerizing transcription factor of the E2F family that, with E2F4, defines a structurally and functionally distinct subfamily and serves as the principal effector of pocket-protein-mediated transcriptional control [PMID:7892279, PMID:7760804, PMID:7542760, PMID:9464260]. It heterodimerizes with DP-1 for high-affinity binding to E2F DNA sites and associates preferentially with the pocket protein p130 rather than pRb or p107 [PMID:7892279, PMID:7760804, PMID:7542760]; this p130 association is required for E2F5's repressive activity in vivo, since E2F5 alone cannot oppose activator E2Fs but does so when co-expressed with p130 [PMID:18385796]. Genetic ablation shows E2F5 is dispensable for normal cell-cycle progression but, redundantly with E2F4, is necessary for p16INK4a/pocket-protein-driven G1 arrest [PMID:11030352]. Beyond proliferative control, E2F5 has prominent roles in terminal differentiation and secretory tissue function: its loss causes choroid plexus secretory dysfunction and hydrocephalus [PMID:9553039], impairs multiciliated cell development in efferent ducts and kidney [PMID:26825228, PMID:30218642], and is required for meiotic recombination during spermatogenesis through direct transactivation of dmc1 [PMID:32196499]. In mammary epithelium E2F5 promotes alveolar progenitor differentiation and acts as a tumor suppressor whose loss, after latency, yields metastatic tumors, with chromatin effects manifest as altered H3K27me3 at luminal progenitor genes [PMID:39341991]. Although classically a repressor, E2F5 functions context-dependently as a transcriptional activator at the HPV18 E6/E7, MYCN, MMP-2/MMP-9, and dmc1 promoters, in the MYCN case through an E2F5-TFDP1-BRG1 complex that deposits activating histone marks [PMID:20639900, PMID:30765227, PMID:32386317, PMID:34746136]. E2F5 subcellular distribution is dynamically regulated: nuclear import depends on its N-terminal 56 residues independent of DP/pRb, CRM1 mediates its nuclear export, and differentiation cues drive its nuclear translocation [PMID:12089160]. Its abundance is controlled post-transcriptionally by METTL3-dependent m6A methylation and by the RNA-binding protein IMP3, both stabilizing E2F5 mRNA [PMID:35985439, PMID:38271139].","teleology":[{"year":1995,"claim":"Establishing that E2F5 is a bona fide E2F-family member required showing it could engage E2F DNA elements and pocket proteins; cloning revealed DP-1 heterodimerization, high-affinity DNA binding, and selective p130 association distinguishing it from pRb-binding activator E2Fs.","evidence":"Yeast two-hybrid, co-immunoprecipitation and DNA-binding assays after cloning","pmids":["7892279","7760804","7542760"],"confidence":"High","gaps":["Did not define the in vivo target gene repertoire","Functional consequence of p130 selectivity not yet tested"]},{"year":1995,"claim":"Whether E2F5 was an activator or repressor was resolved by mapping a C-terminal activation domain that is inactivated upon pocket-protein binding, placing E2F4/E2F5 in a distinct functional subfamily.","evidence":"Reporter assays in yeast and mammalian cells with deletion mutagenesis","pmids":["7542760","9464260"],"confidence":"High","gaps":["Did not establish which mode dominates at endogenous promoters","Co-regulators of activation/repression not identified"]},{"year":1998,"claim":"The physiological non-proliferative role was first revealed when E2F5 knockout mice developed hydrocephalus from choroid plexus secretory dysfunction without cell-cycle defects, decoupling E2F5 from canonical proliferation control.","evidence":"Homozygous knockout mice with histology, EM, and in situ hybridization","pmids":["9553039"],"confidence":"High","gaps":["Secretory target genes in choroid plexus not identified","Mechanism linking E2F5 to fluid production unknown"]},{"year":2000,"claim":"Genetic redundancy with E2F4 was defined by double-knockout neonatal lethality and the failure of double-null fibroblasts to arrest in response to p16INK4a, establishing E2F4/E2F5 as the required effectors of pocket-protein G1 arrest while being dispensable for proliferation per se.","evidence":"E2F4/E2F5 double-knockout mouse genetics and p16INK4a-induced arrest assays","pmids":["11030352"],"confidence":"High","gaps":["Did not resolve E2F4 vs E2F5 individual contributions to arrest","Target genes mediating arrest not enumerated"]},{"year":2000,"claim":"An oncogenic capacity was demonstrated by E2F5 cooperating with DP1 and activated RAS to transform primary kidney cells, hinting at a context where E2F5 drives rather than restrains growth.","evidence":"Focus-formation assay in primary BRK cells with gene mapping","pmids":["10738311"],"confidence":"Medium","gaps":["Transformation in an artificial overexpression context","Did not identify transformation-relevant target genes"]},{"year":2002,"claim":"The basis for E2F5's regulated localization was established by mapping an N-terminal import signal independent of DP/pRb and a CRM1-dependent export region, with differentiation driving nuclear entry.","evidence":"In vitro nuclear import in permeabilized cells, leptomycin B inhibition, and deletion mutagenesis with keratinocyte immunofluorescence","pmids":["12089160"],"confidence":"High","gaps":["Import receptor not identified","Signal triggering differentiation-induced translocation unknown"]},{"year":2008,"claim":"The requirement of p130 for repressive function in vivo was confirmed by showing E2F5 alone cannot block activator-E2F-driven proliferation in lens, but does so when co-expressed with p130.","evidence":"Transgenic mouse crosses with BrdU incorporation and immunohistochemistry","pmids":["18385796"],"confidence":"High","gaps":["Did not test endogenous p130 dependence","Repressed target genes not catalogued"]},{"year":2010,"claim":"The classical repressor view was challenged by identifying E2F5 as a direct activator of HPV18 E6/E7 oncogenes that promotes S-phase entry in HPV18-positive cells, establishing context-dependent activation.","evidence":"Sequential siRNA silencing of E2F members with luciferase reporters and cell-cycle analysis","pmids":["20639900"],"confidence":"Medium","gaps":["Cofactors converting E2F5 to activator not defined","Specificity for HPV18 vs cellular promoters unclear"]},{"year":2011,"claim":"Post-transcriptional control of E2F5 repressor activity was linked to disease by showing mutant-p53-induced miR-128-2 targets E2F5, relieving its repression of p21 and driving chemoresistance.","evidence":"Reporter assays, miRNA overexpression/knockdown and ChIP in NSCLC cells","pmids":["22193543"],"confidence":"Medium","gaps":["Direct E2F5 binding at p21 promoter not shown in this study","Generality beyond NSCLC unknown"]},{"year":2015,"claim":"Direct promoter targets in differentiation were defined by ChIP showing E2F5 represses the differentiation inhibitors ID1 and HMOX1 downstream of miR-98 to control myogenesis.","evidence":"Transcriptomics, miRNA target validation, ChIP, and double-knockdown epistasis in myoblasts","pmids":["25422988"],"confidence":"High","gaps":["Cofactor requirements at these promoters not defined","Whether repression requires p130 not tested"]},{"year":2016,"claim":"Tissue-specific developmental roles in ciliogenesis were established by conditional E2f4/E2f5 deletion eliminating multiciliated and absorptive cells in efferent ducts, causing male sterility from defective fluid absorption.","evidence":"Conditional knockout mouse genetics with histology and immunohistochemistry","pmids":["26825228"],"confidence":"High","gaps":["Direct ciliogenesis target genes not identified","Division of labor between E2F4 and E2F5 unresolved"]},{"year":2016,"claim":"A proliferative signaling axis was proposed in prostate cancer wherein E2F5 acts with p38 to drive linker-region SMAD3 phosphorylation, with co-knockdown causing G1 arrest.","evidence":"siRNA knockdown with Western blot and cell-cycle analysis in PC3 cells and patient tissue","pmids":["26919443"],"confidence":"Medium","gaps":["Direct transcriptional targets of the axis not defined","Whether E2F5 regulates p38 directly unknown"]},{"year":2018,"claim":"Species-specific dominance within the subfamily was revealed in zebrafish where E2f5, not E2f4, is the essential factor for multiciliated cell development in kidney tubules.","evidence":"Zebrafish mutant and double-mutant genetics with whole-mount immunostaining","pmids":["30218642"],"confidence":"High","gaps":["Molecular basis for E2f4/E2f5 functional swap between species unknown","Ciliogenesis targets not identified"]},{"year":2019,"claim":"E2F5 was embedded in oncogenic transcriptional circuits by showing MYCN directly induces E2F5, and E2F5 knockdown reduces CDK2/CDK6 and proliferation in MYCN-amplified neuroblastoma.","evidence":"ChIP, luciferase reporter, siRNA knockdown and Western blot","pmids":["30765227"],"confidence":"Medium","gaps":["Whether E2F5 directly activates CDK2/CDK6 not shown","Feedback onto MYCN not addressed here"]},{"year":2019,"claim":"E2F5 was shown to act as a transcriptional activator in a feed-forward differentiation circuit by binding the lncPCAT1 promoter to drive BMP2 and osteogenic differentiation in periodontal stem cells.","evidence":"ChIP, luciferase reporter, miRNA sponge validation and differentiation assays","pmids":["30997692"],"confidence":"Medium","gaps":["Cofactors enabling activation not defined","Generality across stem cell types unknown"]},{"year":2020,"claim":"Direct activator/repressor duality at metastasis genes was demonstrated by ChIP showing E2F5 represses TFPI2 while activating MMP-2/MMP-9 to promote prostate cancer invasion.","evidence":"ChIP-qPCR with site-directed mutagenesis, reporter assays, zymography and Co-IP in tissue","pmids":["32386317"],"confidence":"High","gaps":["Determinants of activation vs repression at the same factor not defined","Partner proteins at these promoters not identified"]},{"year":2020,"claim":"The in vivo developmental and meiotic program was defined by zebrafish showing E2F5 directly transactivates dmc1 to enable meiotic recombination during spermatogenesis, with dmc1 overexpression rescuing fertility, plus jagged2b activation regulating multiciliated cell fate.","evidence":"Zebrafish mutant genetics, transcriptomics, ChIP on dmc1, and dmc1 rescue with e2f5;tp53 double mutants","pmids":["32196499"],"confidence":"High","gaps":["Cofactors enabling dmc1 activation not identified","Conservation of dmc1 regulation in mammals not tested"]},{"year":2020,"claim":"An anti-apoptotic role was established by showing E2F5 knockdown induces TP53-target pro-apoptotic genes only in wild-type-TP53 breast cancer cells, defining a TP53-dependent suppression of apoptosis.","evidence":"siRNA knockdown with TP53 co-silencing epistasis and cell-death assays in MCF7","pmids":["33000282"],"confidence":"Medium","gaps":["Mechanism linking E2F5 to TP53 target repression not defined","Direct binding at BAX/NOXA/PUMA promoters not shown"]},{"year":2021,"claim":"A physical partner and feedback loop driving E2F5 abundance were identified: CDK13 binds E2F5 and a circCDK13/miR-212-5p/449a axis relieves E2F5 repression to amplify proliferation.","evidence":"Co-IP/mass spectrometry, CRISPR endogenous activation and gain/loss-of-function in vitro and in vivo","pmids":["33390186"],"confidence":"Medium","gaps":["Functional consequence of direct CDK13-E2F5 binding (e.g., phosphorylation) not defined","Reciprocal validation of the interaction limited"]},{"year":2021,"claim":"The mechanism of context-dependent activation was advanced by showing an E2F5-TFDP1-BRG1 complex binds the MYCN promoter and deposits H3 acetylation and H3K4me3 to recruit RNA Pol II during liver regeneration.","evidence":"RNAi, ChIP for BRG1/E2F5/TFDP1, histone modification analysis and MYCN rescue in BRG1-null hepatocytes","pmids":["34746136"],"confidence":"Medium","gaps":["Whether the same complex operates at other activated promoters not tested","Direct E2F5-BRG1 contact not mapped"]},{"year":2021,"claim":"E2F5 was linked to gastric cancer growth by transcriptional upregulation of UBE2T, with UBE2T rescue reversing the phenotype of E2F5 depletion.","evidence":"siRNA knockdown, GSEA, transcription regulation assay and UBE2T rescue","pmids":["34583905"],"confidence":"Low","gaps":["No ChIP confirming direct UBE2T promoter binding","Single lab without mechanistic characterization"]},{"year":2022,"claim":"Post-transcriptional stabilization of E2F5 was defined by demonstrating METTL3-dependent m6A methylation increases E2F5 mRNA stability, with E2F5 overexpression rescuing the anti-tumor effect of METTL3 loss in pancreatic cancer.","evidence":"MeRIP assay, RT-qPCR, Western blot and rescue experiments","pmids":["35985439"],"confidence":"Medium","gaps":["m6A reader mediating stabilization not identified","Site-level m6A mapping on E2F5 not shown"]},{"year":2024,"claim":"A second RNA-based stability mechanism was established by showing IMP3 directly binds E2F5 mRNA and prolongs its half-life, supporting OSCC proliferation.","evidence":"RNA immunoprecipitation, mRNA stability assay, siRNA knockdown and xenograft","pmids":["38271139"],"confidence":"Medium","gaps":["Relationship between IMP3 and METTL3 m6A regulation not addressed","Binding site on E2F5 mRNA not mapped"]},{"year":2024,"claim":"The mammary tumor-suppressor and differentiation role was defined by conditional knockout showing E2F5 promotes alveolar progenitor differentiation via H3K27me3 control at luminal progenitor genes, with loss eventually producing metastatic tumors.","evidence":"Mammary-specific conditional knockout with scRNAseq, H3K27me3 chromatin profiling, RNAseq, WGS and transplantation","pmids":["39341991"],"confidence":"High","gaps":["Mechanism connecting E2F5 to H3K27me3 deposition unknown","Driver events of late metastatic tumors not fully resolved"]},{"year":2025,"claim":"A vascular disease role was added by showing E2F5 promotes VSMC phenotypic switching in diabetic atherosclerosis through Wnt/β-catenin activation, with CyclinE rescuing E2F5 silencing.","evidence":"siRNA knockdown, CyclinE rescue, pharmacological Wnt modulation and in vivo DAS mouse model","pmids":["40890020"],"confidence":"Medium","gaps":["Direct E2F5 targets in the Wnt axis not identified","Whether E2F5 acts upstream or parallel to Wnt unclear"]},{"year":null,"claim":"It remains unresolved what molecular switch converts E2F5 between p130-dependent repression and BRG1/cofactor-dependent activation at individual promoters, and how its differentiation, tumor-suppressor, and oncogenic roles are selected in a given tissue.","evidence":"No timeline study defines a unifying determinant of the activator-repressor switch across contexts","pmids":[],"confidence":"Low","gaps":["No general rule for activation vs repression specificity","Tissue-context determinants of tumor-suppressor vs oncogenic output unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,9,10,18,19,22]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,18,19]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,7,8]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6,7]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[18,19,26]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4,9]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,18,19,22]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,14,15,19,26]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[22,26]}],"complexes":["E2F5-DP1 heterodimer","E2F5-p130 repressor complex","E2F5-TFDP1-BRG1 complex"],"partners":["TFDP1","RBL2","BRG1","CDK13"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15329","full_name":"Transcription factor E2F5","aliases":[],"length_aa":346,"mass_kda":37.6,"function":"Transcriptional activator that binds to E2F sites, these sites are present in the promoter of many genes whose products are involved in cell proliferation. May mediate growth factor-initiated signal transduction. It is likely involved in the early responses of resting cells to growth factor stimulation. Specifically required for multiciliate cell differentiation: together with MCIDAS and E2F5, binds and activate genes required for centriole biogenesis","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q15329/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/E2F5","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/E2F5","total_profiled":1310},"omim":[{"mim_id":"621288","title":"LIN52 DREAM MUVB CORE COMPLEX COMPONENT; LIN52","url":"https://www.omim.org/entry/621288"},{"mim_id":"621287","title":"LIN37 DREAM MUVB CORE COMPLEX COMPONENT; LIN37","url":"https://www.omim.org/entry/621287"},{"mim_id":"618627","title":"GERM CELL-LESS 1, SPERMATOGENESIS-ASSOCIATED; GMCL1","url":"https://www.omim.org/entry/618627"},{"mim_id":"613367","title":"LIN54, C. ELEGANS, HOMOLOG OF; LIN54","url":"https://www.omim.org/entry/613367"},{"mim_id":"609375","title":"LIN9 DREAM MUVB CORE COMPLEX COMPONENT; LIN9","url":"https://www.omim.org/entry/609375"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Additional"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":27.7}],"url":"https://www.proteinatlas.org/search/E2F5"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"Q15329","domains":[{"cath_id":"1.10.10.10","chopping":"50-113","consensus_level":"high","plddt":84.9714,"start":50,"end":113},{"cath_id":"-","chopping":"174-232","consensus_level":"medium","plddt":89.6908,"start":174,"end":232},{"cath_id":"1.20.5","chopping":"123-167","consensus_level":"high","plddt":93.5436,"start":123,"end":167}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15329","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15329-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15329-F1-predicted_aligned_error_v6.png","plddt_mean":70.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=E2F5","jax_strain_url":"https://www.jax.org/strain/search?query=E2F5"},"sequence":{"accession":"Q15329","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15329.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15329/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15329"}},"corpus_meta":[{"pmid":"7892279","id":"PMC_7892279","title":"E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7892279","citation_count":326,"is_preprint":false},{"pmid":"11030352","id":"PMC_11030352","title":"E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control.","date":"2000","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/11030352","citation_count":237,"is_preprint":false},{"pmid":"7760804","id":"PMC_7760804","title":"E2F-5, a new E2F family member that interacts with p130 in vivo.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7760804","citation_count":223,"is_preprint":false},{"pmid":"9553039","id":"PMC_9553039","title":"A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targeting.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9553039","citation_count":153,"is_preprint":false},{"pmid":"28232182","id":"PMC_28232182","title":"SNHG16 contributes to breast cancer cell migration by competitively binding miR-98 with E2F5.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28232182","citation_count":139,"is_preprint":false},{"pmid":"22193543","id":"PMC_22193543","title":"MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function.","date":"2011","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22193543","citation_count":134,"is_preprint":false},{"pmid":"30185212","id":"PMC_30185212","title":"The putative tumour suppressor miR-1-3p modulates prostate cancer cell aggressiveness by repressing E2F5 and PFTK1.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30185212","citation_count":65,"is_preprint":false},{"pmid":"27259277","id":"PMC_27259277","title":"The transcription factor FOXN3 inhibits cell proliferation by downregulating E2F5 expression in hepatocellular carcinoma cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27259277","citation_count":52,"is_preprint":false},{"pmid":"7542760","id":"PMC_7542760","title":"Molecular and functional characterisation of E2F-5, a new member of the E2F family.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7542760","citation_count":52,"is_preprint":false},{"pmid":"27398145","id":"PMC_27398145","title":"MicroRNA-154 inhibits growth and invasion of breast cancer cells through targeting E2F5.","date":"2016","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/27398145","citation_count":51,"is_preprint":false},{"pmid":"24529171","id":"PMC_24529171","title":"Up-regulated MicroRNA-181a induces carcinogenesis in hepatitis B virus-related hepatocellular carcinoma by targeting E2F5.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24529171","citation_count":50,"is_preprint":false},{"pmid":"26825228","id":"PMC_26825228","title":"E2f4 and E2f5 are essential for the development of the male reproductive system.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/26825228","citation_count":48,"is_preprint":false},{"pmid":"33390186","id":"PMC_33390186","title":"CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/33390186","citation_count":48,"is_preprint":false},{"pmid":"30666158","id":"PMC_30666158","title":"Long noncoding RNA SNHG6 functions as a competing endogenous RNA by sponging miR-181a-5p to regulate E2F5 expression in colorectal cancer.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/30666158","citation_count":46,"is_preprint":false},{"pmid":"21274376","id":"PMC_21274376","title":"A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma.","date":"2011","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/21274376","citation_count":46,"is_preprint":false},{"pmid":"19259095","id":"PMC_19259095","title":"Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome.","date":"2009","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19259095","citation_count":43,"is_preprint":false},{"pmid":"26103003","id":"PMC_26103003","title":"MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer.","date":"2015","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26103003","citation_count":40,"is_preprint":false},{"pmid":"10738311","id":"PMC_10738311","title":"Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors.","date":"2000","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10738311","citation_count":40,"is_preprint":false},{"pmid":"27186275","id":"PMC_27186275","title":"miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells.","date":"2016","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/27186275","citation_count":40,"is_preprint":false},{"pmid":"20181230","id":"PMC_20181230","title":"E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.","date":"2010","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20181230","citation_count":40,"is_preprint":false},{"pmid":"29859832","id":"PMC_29859832","title":"MicroRNA-1179 inhibits the proliferation, migration and invasion of human pancreatic cancer cells by targeting E2F5.","date":"2018","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/29859832","citation_count":39,"is_preprint":false},{"pmid":"28351331","id":"PMC_28351331","title":"MiR-613 suppresses retinoblastoma cell proliferation, invasion, and tumor formation by targeting E2F5.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28351331","citation_count":38,"is_preprint":false},{"pmid":"27074041","id":"PMC_27074041","title":"miRNA-154-5p Inhibits Proliferation, Migration and Invasion by Targeting E2F5 in Prostate Cancer Cell Lines.","date":"2016","source":"Urologia internationalis","url":"https://pubmed.ncbi.nlm.nih.gov/27074041","citation_count":37,"is_preprint":false},{"pmid":"30392041","id":"PMC_30392041","title":"Induction of apoptosis in ovarian cancer cells by miR-493-3p directly targeting AKT2, STK38L, HMGA2, ETS1 and E2F5.","date":"2018","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/30392041","citation_count":37,"is_preprint":false},{"pmid":"30997692","id":"PMC_30997692","title":"A feed-forward regulatory network lncPCAT1/miR-106a-5p/E2F5 regulates the osteogenic differentiation of periodontal ligament stem cells.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30997692","citation_count":36,"is_preprint":false},{"pmid":"12089160","id":"PMC_12089160","title":"Active nuclear import and export pathways regulate E2F-5 subcellular localization.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12089160","citation_count":36,"is_preprint":false},{"pmid":"29509253","id":"PMC_29509253","title":"MicroRNA-129-3p suppresses tumor growth by targeting E2F5 in glioblastoma.","date":"2018","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29509253","citation_count":35,"is_preprint":false},{"pmid":"32196499","id":"PMC_32196499","title":"E2f5 is a versatile transcriptional activator required for spermatogenesis and multiciliated cell differentiation in zebrafish.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32196499","citation_count":34,"is_preprint":false},{"pmid":"32386317","id":"PMC_32386317","title":"E2F5 promotes prostate cancer cell migration and invasion through regulation of TFPI2, MMP-2 and MMP-9.","date":"2020","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/32386317","citation_count":33,"is_preprint":false},{"pmid":"32420810","id":"PMC_32420810","title":"Circular RNA ABCB10 promotes non-small cell lung cancer progression by increasing E2F5 expression through sponging miR-584-5p.","date":"2020","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/32420810","citation_count":32,"is_preprint":false},{"pmid":"23803041","id":"PMC_23803041","title":"Effects of microRNA-106 on proliferation of gastric cancer cell through regulating p21 and E2F5.","date":"2013","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23803041","citation_count":29,"is_preprint":false},{"pmid":"30218642","id":"PMC_30218642","title":"Distinct requirements of E2f4 versus E2f5 activity for multiciliated cell development in the zebrafish embryo.","date":"2018","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/30218642","citation_count":29,"is_preprint":false},{"pmid":"28599485","id":"PMC_28599485","title":"miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28599485","citation_count":29,"is_preprint":false},{"pmid":"33116856","id":"PMC_33116856","title":"LncRNA MALAT1 Regulates the Progression and Cisplatin Resistance of Ovarian Cancer Cells via Modulating miR-1271-5p/E2F5 Axis.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/33116856","citation_count":26,"is_preprint":false},{"pmid":"26919443","id":"PMC_26919443","title":"Deregulated E2F5/p38/SMAD3 Circuitry Reinforces the Pro-Tumorigenic Switch of TGFβ Signaling in Prostate Cancer.","date":"2016","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26919443","citation_count":25,"is_preprint":false},{"pmid":"16172982","id":"PMC_16172982","title":"Changes in E2F5 intracellular localization in mouse and human choroid plexus epithelium with development.","date":"2005","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16172982","citation_count":23,"is_preprint":false},{"pmid":"35985439","id":"PMC_35985439","title":"METTL3 promotes the growth and metastasis of pancreatic cancer by regulating the m6A modification and stability of E2F5.","date":"2022","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/35985439","citation_count":23,"is_preprint":false},{"pmid":"23377984","id":"PMC_23377984","title":"Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.","date":"2013","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23377984","citation_count":22,"is_preprint":false},{"pmid":"34348712","id":"PMC_34348712","title":"CircFAM13B promotes the proliferation of hepatocellular carcinoma by sponging miR-212, upregulating E2F5 expression and activating the P53 pathway.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34348712","citation_count":19,"is_preprint":false},{"pmid":"30765227","id":"PMC_30765227","title":"MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/30765227","citation_count":17,"is_preprint":false},{"pmid":"31257477","id":"PMC_31257477","title":"miR‑132 inhibits high glucose‑induced vascular smooth muscle cell proliferation and migration by targeting E2F5.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/31257477","citation_count":16,"is_preprint":false},{"pmid":"16546434","id":"PMC_16546434","title":"Involvement of protein kinase C and E2F-5 in euxanthone-induced neurite differentiation of neuroblastoma.","date":"2006","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16546434","citation_count":16,"is_preprint":false},{"pmid":"25422988","id":"PMC_25422988","title":"miR-98 delays skeletal muscle differentiation by down-regulating E2F5.","date":"2015","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/25422988","citation_count":15,"is_preprint":false},{"pmid":"33595944","id":"PMC_33595944","title":"Downregulation of long non-coding RNA UCA1 represses tumorigenesis and metastasis of osteosarcoma via miR-513b-5p/E2F5 axis.","date":"2021","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/33595944","citation_count":15,"is_preprint":false},{"pmid":"34746136","id":"PMC_34746136","title":"An E2F5-TFDP1-BRG1 Complex Mediates Transcriptional Activation of MYCN in Hepatocytes.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34746136","citation_count":14,"is_preprint":false},{"pmid":"20639900","id":"PMC_20639900","title":"The E2F5 repressor is an activator of E6/E7 transcription and of the S-phase entry in HPV18-associated cells.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20639900","citation_count":14,"is_preprint":false},{"pmid":"34583905","id":"PMC_34583905","title":"E2F5 promotes proliferation and invasion of gastric cancer through directly upregulating UBE2T transcription.","date":"2021","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/34583905","citation_count":13,"is_preprint":false},{"pmid":"29362021","id":"PMC_29362021","title":"Let-7c Inhibits the Proliferation, Invasion, and Migration of Glioma Cells via Targeting E2F5.","date":"2018","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/29362021","citation_count":13,"is_preprint":false},{"pmid":"17295207","id":"PMC_17295207","title":"E2F5 and LEK1 translocation to the nucleus is an early event demarcating myoblast quiescence.","date":"2007","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17295207","citation_count":13,"is_preprint":false},{"pmid":"9464260","id":"PMC_9464260","title":"The molecular and functional characterization of E2F-5 transcription factor.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9464260","citation_count":13,"is_preprint":false},{"pmid":"32414231","id":"PMC_32414231","title":"MicroRNA-1271-5p inhibits the tumorigenesis of ovarian cancer through targeting E2F5 and negatively regulates the mTOR signaling pathway.","date":"2020","source":"Panminerva medica","url":"https://pubmed.ncbi.nlm.nih.gov/32414231","citation_count":12,"is_preprint":false},{"pmid":"19014670","id":"PMC_19014670","title":"Thyroid hormone - triiodothyronine - has contrary effect on proliferation of human proximal tubules cell line (HK2) and renal cancer cell lines (Caki-2, Caki-1) - role of E2F4, E2F5 and p107, p130.","date":"2008","source":"Thyroid research","url":"https://pubmed.ncbi.nlm.nih.gov/19014670","citation_count":12,"is_preprint":false},{"pmid":"33788723","id":"PMC_33788723","title":"Targeting CALM2 Inhibits Hepatocellular Carcinoma Growth and Metastasis by Suppressing E2F5-mediated Cell Cycle Progression.","date":"2021","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33788723","citation_count":11,"is_preprint":false},{"pmid":"8589754","id":"PMC_8589754","title":"Structural characterization and specificity of expression of E2F-5: a new member of the E2F family of transcription factors.","date":"1995","source":"Cellular & molecular biology research","url":"https://pubmed.ncbi.nlm.nih.gov/8589754","citation_count":11,"is_preprint":false},{"pmid":"33734894","id":"PMC_33734894","title":"E2F5 Promotes the Malignancy of Ovarian Cancer Via the Regulation of Hippo and Wnt Pathways.","date":"2021","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/33734894","citation_count":9,"is_preprint":false},{"pmid":"33000282","id":"PMC_33000282","title":"Knockdown of E2F5 induces cell death via the TP53‑dependent pathway in breast cancer cells carrying wild‑type TP53.","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33000282","citation_count":9,"is_preprint":false},{"pmid":"37827344","id":"PMC_37827344","title":"LINC01980 induced by TGF-beta promotes hepatocellular carcinoma metastasis via miR-376b-5p/E2F5 axis.","date":"2023","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/37827344","citation_count":9,"is_preprint":false},{"pmid":"36979479","id":"PMC_36979479","title":"MAPK Is a Mutual Pathway Targeted by Anxiety-Related miRNAs, and E2F5 Is a Putative Target for Anxiolytic miRNAs.","date":"2023","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36979479","citation_count":9,"is_preprint":false},{"pmid":"18385796","id":"PMC_18385796","title":"Overexpression of E2F5/p130, but not E2F5 alone, can inhibit E2F-induced cell cycle entry in transgenic mice.","date":"2008","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/18385796","citation_count":8,"is_preprint":false},{"pmid":"34784267","id":"PMC_34784267","title":"CircFOXM1 promotes the proliferation, migration, invasion, and glutaminolysis of glioblastoma by regulating the miR-577/E2F5 axis.","date":"2022","source":"Bosnian journal of basic medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34784267","citation_count":8,"is_preprint":false},{"pmid":"34947956","id":"PMC_34947956","title":"Inhibition of HDACs Suppresses Cell Proliferation and Cell Migration of Gastric Cancer by Regulating E2F5 Targeting BCL2.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34947956","citation_count":6,"is_preprint":false},{"pmid":"11883315","id":"PMC_11883315","title":"[Differences in human and rat FSH receptors promote activity as a result of the transcriptional factors: E2F1, E2F4 and E2F5 overexpression].","date":"2001","source":"Ginekologia polska","url":"https://pubmed.ncbi.nlm.nih.gov/11883315","citation_count":6,"is_preprint":false},{"pmid":"31983127","id":"PMC_31983127","title":"MicroRNA‑34a inhibits esophageal squamous cell carcinoma progression by targeting E2F5.","date":"2019","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31983127","citation_count":5,"is_preprint":false},{"pmid":"38087129","id":"PMC_38087129","title":"E2F5 Targeted by Let-7d-5p Facilitates Cell Proliferation, Metastasis and Immune Escape in Gallbladder Cancer.","date":"2023","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38087129","citation_count":4,"is_preprint":false},{"pmid":"35909488","id":"PMC_35909488","title":"hsa_circ_0084811 Regulates Cell Proliferation and Apoptosis in Retinoblastoma through miR-18a-5p/miR-18b-5p/E2F5 Axis.","date":"2022","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/35909488","citation_count":4,"is_preprint":false},{"pmid":"27382388","id":"PMC_27382388","title":"Aberrant Promoter Methylation at CpG Cytosines Induce the Upregulation of the E2F5 Gene in Breast Cancer.","date":"2016","source":"Journal of breast cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27382388","citation_count":4,"is_preprint":false},{"pmid":"38271139","id":"PMC_38271139","title":"Knockdown of RNA-binding protein IMP3 suppresses oral squamous cell carcinoma proliferation by destabilizing E2F5 transcript.","date":"2024","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/38271139","citation_count":3,"is_preprint":false},{"pmid":"39341991","id":"PMC_39341991","title":"Insight into mammary gland development and tumor progression in an E2F5 conditional knockout mouse model.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/39341991","citation_count":3,"is_preprint":false},{"pmid":"19578977","id":"PMC_19578977","title":"Identification and expression analysis of two zebrafish E2F5 genes during oogenesis and development.","date":"2009","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/19578977","citation_count":3,"is_preprint":false},{"pmid":"40890020","id":"PMC_40890020","title":"E2F5 Accelerates Vascular Smooth Muscle Cells Phenotype Switching in Diabetic Atherosclerosis through Activating Wnt/β-Catenin Pathway.","date":"2025","source":"Diabetes & metabolism journal","url":"https://pubmed.ncbi.nlm.nih.gov/40890020","citation_count":1,"is_preprint":false},{"pmid":"37847082","id":"PMC_37847082","title":"[Effects of lncRNA SNHG12 on the proliferation, migration and invasiveness of prostate cancer cells by regulating E2F5 expression].","date":"2023","source":"Zhonghua nan ke xue = National journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/37847082","citation_count":1,"is_preprint":false},{"pmid":"39907045","id":"PMC_39907045","title":"Investigating the clinical significance of E2F5 expression in circulating extracellular vesicles in prostate carcinoma.","date":"2025","source":"Urologia","url":"https://pubmed.ncbi.nlm.nih.gov/39907045","citation_count":1,"is_preprint":false},{"pmid":"38550126","id":"PMC_38550126","title":"Retracted: hsa_circ_0084811 Regulates Cell Proliferation and Apoptosis in Retinoblastoma through miR-18a-5p/miR-18b-5p/E2F5 Axis.","date":"2024","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/38550126","citation_count":1,"is_preprint":false},{"pmid":"41488283","id":"PMC_41488283","title":"E2F5 Overexpression in Laryngeal Squamous Cell Carcinoma: Associations With Neutrophil Extracellular Traps in the Tumor Microenvironment.","date":"2025","source":"World journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41488283","citation_count":0,"is_preprint":false},{"pmid":"41226814","id":"PMC_41226814","title":"circ_0000132 Regulates Chicken Granulosa Cell Proliferation Apoptosis and E2/P4 Synthesis via miR-206 E2F5 Signaling.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41226814","citation_count":0,"is_preprint":false},{"pmid":"41987367","id":"PMC_41987367","title":"E2F5 Promotes Vascular Endothelial Cell Proliferation and Angiogenesis in Diabetic Lower Limb Ischemia via an Autophagy-Related Mechanism.","date":"2026","source":"Circulation journal : official journal of the Japanese Circulation Society","url":"https://pubmed.ncbi.nlm.nih.gov/41987367","citation_count":0,"is_preprint":false},{"pmid":"41522321","id":"PMC_41522321","title":"Fu Zheng Xiao Yu San Jie Decoction affects the proliferation of renal cell carcinoma via regulating E2F5 gene.","date":"2025","source":"Translational andrology and urology","url":"https://pubmed.ncbi.nlm.nih.gov/41522321","citation_count":0,"is_preprint":false},{"pmid":"41908971","id":"PMC_41908971","title":"Crosstalk Between FOXN3 and E2F5 Reveals a Novel Tumor Suppressive Pathway in Acute Myeloid Leukemia via MAPK Signaling: Implications for Potential Future Targeted Therapy.","date":"2026","source":"Blood and lymphatic cancer : targets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/41908971","citation_count":0,"is_preprint":false},{"pmid":"37228644","id":"PMC_37228644","title":"Long Noncoding RNA SNHG6 Functions as a Competing Endogenous RNA by Sponging miR-181a-5p to Regulate E2F5 Expression in Colorectal Cancer [Retraction].","date":"2023","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/37228644","citation_count":0,"is_preprint":false},{"pmid":"35173889","id":"PMC_35173889","title":"miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells [Retraction].","date":"2022","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/35173889","citation_count":0,"is_preprint":false},{"pmid":"42057744","id":"PMC_42057744","title":"An Integrated Graphene-MXene Electrochemical Transistor Array Platform for Accurate Prostate Cancer Diagnosis Using Plasma sEV-Derived E2F5 Biomarker.","date":"2026","source":"Small (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/42057744","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.27.625731","title":"Mammary Alveolar Proliferation and Differentiation During Early Pregnancy is Regulated by E2F5","date":"2024-11-27","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.27.625731","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":42910,"output_tokens":7092,"usd":0.117555,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16161,"output_tokens":7131,"usd":0.12954,"stage2_stop_reason":"end_turn"},"total_usd":0.247095,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"E2F-5 protein was cloned and shown to heterodimerize with DP-1, enabling high-affinity binding to E2F DNA recognition sequences. E2F-5 preferentially interacts with p130 (not pRb) in a yeast two-hybrid assay, in contrast to E2F-1, -2, and -3 which bind pRb.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, DNA binding assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — independently replicated across multiple labs in the same year (PMID 7892279, 7760804, 7542760) using yeast two-hybrid, in vitro binding, and cell-based assays\",\n      \"pmids\": [\"7892279\", \"7760804\", \"7542760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"E2F-5 contains a potent transcriptional activation domain in its C-terminal region that functions in both yeast and mammalian cells and is specifically inactivated upon pocket protein binding. E2F-5 and E2F-4 define a subfamily structurally and functionally distinct from E2F-1, -2, and -3.\",\n      \"method\": \"Reporter gene assays in yeast and mammalian cells, deletion mutagenesis, two-hybrid assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — functional domain mapping with mutagenesis confirmed in both yeast and mammalian systems, replicated across labs\",\n      \"pmids\": [\"7542760\", \"9464260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Under physiological conditions, E2F-5 interacts preferentially with p130 (not pRb or p107) as demonstrated by specific antiserum immunoprecipitation from cell extracts.\",\n      \"method\": \"Co-immunoprecipitation with specific E2F-5 antiserum\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with specific antiserum, replicated by multiple independent labs\",\n      \"pmids\": [\"7760804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"E2F-5 knockout mice develop nonobstructive hydrocephalus with excessive CSF production from the choroid plexus. E2F-5 CNS expression is largely confined to the choroid plexus, and its loss affects secretory behavior of this differentiated neural tissue without perturbing cell cycle kinetics in knockout fibroblasts.\",\n      \"method\": \"Gene targeting (homozygous knockout mice), histology, electron microscopy, in situ hybridization\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO mouse model with specific phenotypic readout and localization data, single rigorous study with multiple orthogonal methods\",\n      \"pmids\": [\"9553039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Simultaneous inactivation of E2F4 and E2F5 in mice results in neonatal lethality. Embryonic fibroblasts from E2F4/E2F5 double-knockout mice fail to arrest in G1 in response to p16INK4a, demonstrating that E2F4 and E2F5 are dispensable for cell cycle progression but necessary for pocket protein-mediated G1 arrest.\",\n      \"method\": \"Double-knockout mouse genetics, cell cycle analysis, p16INK4a-induced arrest assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double-knockout mice and defined cellular phenotype, single rigorous study with multiple functional readouts\",\n      \"pmids\": [\"11030352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"E2F5 gene (mapped to 8q21.1-21.3) can promote morphologically transformed foci in primary baby rat kidney cells when overexpressed with DP1 and activated RAS, demonstrating oncogenic cooperation analogous to MYC-type cooperating oncogenes.\",\n      \"method\": \"Focus formation assay in primary BRK cells, gene mapping, copy number analysis in breast tumors\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional transformation assay with defined partners, single lab, complemented by chromosomal mapping\",\n      \"pmids\": [\"10738311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"E2F-5 nuclear import requires only the first N-terminal 56 amino acids and is independent of DP or pRB family proteins. E2F-5 is exported from the nucleus via CRM1-mediated (leptomycin B-sensitive) transport through a region corresponding to amino acid residues 130-154, which excludes the DNA- and p130-binding domains. Keratinocyte differentiation drives E2F-5 nuclear translocation.\",\n      \"method\": \"In vitro nuclear import assays in digitonin-permeabilized cells, leptomycin B inhibition, deletion mutant analysis, immunofluorescence in keratinocytes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro nuclear import reconstitution combined with domain mutagenesis and pharmacological inhibition, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"12089160\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"E2F5 protein localizes to the nucleus in immature/proliferating choroid plexus epithelial cells and shifts to the cytoplasm as cells mature (change from pseudostratified to cuboidal epithelium), a change that does not correlate with PCNA-positive proliferating cells but parallels morphological maturation.\",\n      \"method\": \"Immunohistochemistry, in situ hybridization, PCNA co-staining in mouse and human developing choroid plexus\",\n      \"journal\": \"The International journal of developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization by IHC across developmental stages in two species, but no functional manipulation\",\n      \"pmids\": [\"16172982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"E2F5 and LEK1 translocate to the nucleus as an early event in Raf/MEK/ERK-driven myoblast quiescence. Disruption of MEK1 activity prevents ERK1/2 phosphorylation and nuclear translocation of E2F5 and LEK1. E2F5 and LEK1 are found in nuclei of non-dividing satellite cells and myonuclei in vivo.\",\n      \"method\": \"Proteomics (2D-gel + MS), immunofluorescence, pharmacological MEK inhibition, in vivo satellite cell staining\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — proteomic identification plus pharmacological epistasis and in vivo correlation, single lab\",\n      \"pmids\": [\"17295207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Overexpression of E2F5 alone is not sufficient to inhibit E2F1- or E2F3a-induced cell cycle reentry in lens fiber cells in vivo. However, coexpression of E2F5 together with p130 inhibits activator E2F-mediated cell proliferation, confirming that p130 is required for E2F5's repressive activity.\",\n      \"method\": \"Transgenic mouse crossing experiments, BrdU incorporation, immunohistochemistry, in situ hybridization\",\n      \"journal\": \"Molecular vision\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo with multiple transgenic combinations and functional proliferation readout, single lab with rigorous controls\",\n      \"pmids\": [\"18385796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"E2F5 acts as a direct transcriptional activator (not repressor) of HPV18 E6/E7 oncogenes by binding E2F sites specific to HPV18 in HeLa cells. Sequential silencing of E2F family members identified E2F5 as the activator. E2F5 also positively regulates S-phase entry specifically in HPV18-expressing cells.\",\n      \"method\": \"Sequential siRNA silencing of E2F family members, luciferase reporter assays, cell cycle analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — sequential silencing with reporter validation, functional cell cycle assay, single lab\",\n      \"pmids\": [\"20639900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"miR-128-2, induced by mutant p53 (p53R175H), post-transcriptionally targets E2F5 and abrogates its repressive activity on p21(waf1) transcription. Loss of E2F5 repression leads to cytoplasmic p21 accumulation which prevents pro-caspase-3 cleavage, contributing to chemoresistance in non-small-cell lung cancer.\",\n      \"method\": \"Reporter assays, Western blot, miRNA overexpression/knockdown, ChIP for mutant p53 on ARPP21 promoter\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — miRNA target validation plus mechanistic pathway linking E2F5 to p21 transcription and apoptosis, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"22193543\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"E2F5 is a direct target of miR-98 in human myoblasts, and E2F5 binds to the promoters of the differentiation inhibitors ID1 and HMOX1, repressing their expression. Simultaneous knockdown of E2F5 and miR-98 restores normal skeletal muscle differentiation, placing E2F5 downstream of miR-98 in regulating myogenesis.\",\n      \"method\": \"Transcriptomic analysis, direct miRNA target validation, ChIP on ID1 and HMOX1 promoters, genetic epistasis by double knockdown\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct promoter binding plus genetic epistasis with rescue experiment, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25422988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"E2F5 overexpression is associated with elevated p38 phosphorylation and SMAD3 phosphorylation at the linker region (Ser-208, pSMAD3L) in prostate cancer. Downregulation of E2F5 and p38 by siRNA in PC3 cells reduces SMAD3 phosphorylation and causes G1 cell cycle arrest, defining an E2F5/p38/SMAD3 axis in prostate cancer proliferation.\",\n      \"method\": \"siRNA knockdown, Western blot, immunostaining, qRT-PCR, cell cycle analysis\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — siRNA epistasis with molecular readouts in cell line and patient tissue, single lab\",\n      \"pmids\": [\"26919443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"E2f4 and E2f5 are required for the development of multiciliated cells and absorptive cells in efferent ducts; conditional deletion of E2f4 in Vil-cre;E2f5+/- males eliminates multiciliated cells and reduces aquaporin1 and clusterin expression in efferent ducts, causing male sterility due to defective fluid absorption.\",\n      \"method\": \"Conditional knockout mouse genetics (Vil-cre;E2f4f/f;E2f5+/-), histology, immunohistochemistry\",\n      \"journal\": \"Cell cycle (Georgetown, Tex.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean conditional KO with specific molecular and cellular phenotype, single lab with multiple orthogonal readouts\",\n      \"pmids\": [\"26825228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In zebrafish, E2f5 is essential for MCC development in kidney tubules, while E2f4 is dispensable. Using double mutant combinations, E2f5 has a more prominent role than E2f4 in zebrafish MCC development, contrasting with the mouse where E2f4 appears dominant.\",\n      \"method\": \"Zebrafish mutant genetics, double mutant analysis, whole mount immunostaining\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with multiple mutant combinations in defined tissue, replicated findings across groups\",\n      \"pmids\": [\"30218642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MYCN directly binds an E-Box motif in the E2F5 gene promoter to induce its transcription, as confirmed by ChIP and reporter assays. E2F5 knockdown in MYCN-amplified neuroblastoma cells inhibits proliferation and reduces CDK2 and CDK6 expression.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, siRNA knockdown, Western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay establishing direct transcriptional regulation, single lab\",\n      \"pmids\": [\"30765227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"E2F5 can bind to the promoter of lncPCAT1 in periodontal ligament stem cells, forming a feed-forward regulatory network in which E2F5 drives lncPCAT1 expression which in turn sponges miR-106a-5p to upregulate BMP2, promoting osteogenic differentiation.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, miRNA sponge validation, osteogenic differentiation assays in vitro and in vivo\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay with functional osteogenic differentiation readout, single lab\",\n      \"pmids\": [\"30997692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"E2F5 promotes prostate cancer cell migration and invasion by acting as a transcriptional activator/repressor at TFPI2, MMP-2, and MMP-9 promoters. ChIP with anti-E2F5 IgG confirmed E2F5 recruitment to these promoters; E2F5 represses TFPI2 and activates MMP-2/MMP-9, increasing gelatinolytic activity.\",\n      \"method\": \"RNAi knockdown, pathway-focused gene expression profiling, ChIP-qPCR, site-directed mutagenesis, dual-luciferase assay, Proteome Profiler array, gelatin zymography, co-immunoprecipitation in tissue\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP with mutagenesis and multiple orthogonal methods (reporter, proteome profiler, zymography, Co-IP in tissue), single lab\",\n      \"pmids\": [\"32386317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"E2F5 knockout in zebrafish causes spermatogenesis arrest at the zygotene stage due to homologous recombination defects and germ cell apoptosis. E2F5 directly binds the promoter of dmc1 (meiotic recombination protein) to promote its transcription; overexpression of dmc1 rescues fertilization in e2f5 mutant males. E2f5 also activates the Notch pathway gene jagged2b to inhibit MCC fate acquisition by neighboring principal cells.\",\n      \"method\": \"Zebrafish mutant genetics, transcriptome analysis, ChIP on dmc1 promoter, dmc1 rescue by overexpression, double mutant analysis (e2f5;tp53)\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP demonstrating direct promoter binding plus genetic rescue with dmc1, multiple double-mutant combinations and transcriptomics, single lab with comprehensive orthogonal methods\",\n      \"pmids\": [\"32196499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"E2F5 knockdown in wild-type TP53-bearing breast cancer cells (MCF7) induces cell death through upregulation of TP53-target pro-apoptotic genes (BAX, NOXA, PUMA). This effect is abrogated by TP53 silencing and is not observed in mutant TP53 cells, indicating E2F5 suppresses TP53-mediated apoptosis in a TP53-dependent manner.\",\n      \"method\": \"siRNA knockdown, real-time RT-qPCR, TP53 co-silencing epistasis experiment, cell death assays\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (E2F5 KD + TP53 KD) with defined molecular readouts, single lab\",\n      \"pmids\": [\"33000282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDK13 physically interacts with E2F5 (confirmed by Co-IP coupled to mass spectrometry) and this interaction strengthens the pro-proliferation effect of CDK13. Transcriptional activation of CDK13 promotes E2F5 protein expression by facilitating circCDK13 biogenesis, which sponges miR-212-5p/449a to relieve repression of E2F5, forming a positive feedback loop.\",\n      \"method\": \"Co-immunoprecipitation plus mass spectrometry, CRISPR-Cas9 endogenous activation, loss/gain-of-function assays in vitro and in vivo\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP/MS identifying physical interaction, CRISPR-based endogenous activation, single lab\",\n      \"pmids\": [\"33390186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"An E2F5-TFDP1-BRG1 complex binds the MYCN promoter in hepatocytes to drive MYCN transcription during liver regeneration. BRG1 is recruited by E2F5/TFDP1 and promotes histone H3 acetylation and H3K4 trimethylation at the MYCN promoter, facilitating RNA polymerase II binding.\",\n      \"method\": \"RNA interference validation of E2F5 and TFDP1, ChIP for BRG1/E2F5/TFDP1 at MYCN promoter, histone modification analysis, MYCN overexpression rescue in BRG1-null hepatocytes\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP establishing complex recruitment with histone modification readout and genetic rescue, single lab\",\n      \"pmids\": [\"34746136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"E2F5 directly upregulates UBE2T transcription in gastric cancer cells, as confirmed by correlation analysis and transcriptional regulation assays. E2F5 depletion inhibits proliferation and invasion, and UBE2T overexpression reverses these effects.\",\n      \"method\": \"siRNA knockdown, GSEA, correlation analysis, transcription regulation assay, rescue by UBE2T overexpression\",\n      \"journal\": \"Digestive and liver disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — transcriptional regulation assay without detailed mechanistic characterization (no ChIP reported in abstract), single lab\",\n      \"pmids\": [\"34583905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"METTL3 promotes E2F5 mRNA stability through m6A methylation of E2F5 transcripts, as demonstrated by MeRIP assay. Silencing METTL3 decreases E2F5 expression and inhibits pancreatic cancer cell viability; overexpression of E2F5 reverses the anti-tumor effects of METTL3 knockdown.\",\n      \"method\": \"MeRIP assay (m6A methylation), RT-qPCR, Western blot, CCK-8, rescue experiments\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeRIP directly measuring m6A modification of E2F5 mRNA plus functional epistasis rescue, single lab\",\n      \"pmids\": [\"35985439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IMP3 (RNA-binding protein) binds E2F5 mRNA directly (confirmed by RNA immunoprecipitation), and silencing IMP3 shortens E2F5 mRNA half-life and reduces E2F5 protein expression, thereby inhibiting OSCC cell proliferation.\",\n      \"method\": \"RNA immunoprecipitation (RIP), mRNA stability assay, siRNA knockdown, in vivo xenograft\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP establishing direct mRNA-protein interaction with functional mRNA stability measurement, single lab\",\n      \"pmids\": [\"38271139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Mammary-specific conditional knockout of E2F5 results in delayed alveolar expansion during early pregnancy with reduced E2F target gene expression. E2F5 deletion leads to enrichment of luminal progenitor populations at the expense of differentiated alveolar cells, with depletion of the repressive H3K27me3 mark at luminal progenitor-associated genes. After prolonged latency, E2F5 conditional knockout mice develop highly metastatic mammary tumors with altered Cyclin D1 levels.\",\n      \"method\": \"scRNAseq, mammary-specific conditional knockout, chromatin profiling (H3K27me3), RNAseq, whole genome sequencing, transplantation assay, Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with chromatin profiling, transcriptomics, and multiple functional readouts, single rigorous study with comprehensive orthogonal methods\",\n      \"pmids\": [\"39341991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"E2F5 loss leads to delayed alveolar expansion during early pregnancy with reduced proliferation (decreased canonical E2F target gene expression) and a block in luminal progenitor differentiation into alveolar precursors, associated with depletion of H3K27me3 at luminal progenitor genes. E2F5 chromatin binding increases during early pregnancy.\",\n      \"method\": \"Mammary epithelial-specific conditional knockout, scRNAseq, chromatin profiling, RNAseq\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — preprint with conditional KO and chromatin profiling, not yet peer-reviewed, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"E2F5 promotes VSMC phenotypic switching in diabetic atherosclerosis through activation of the Wnt/β-catenin pathway. E2F5 knockdown inhibits phenotypic transformation of VSMCs, and CyclinE overexpression reverses this inhibition. BML-284 (Wnt activator) attenuates the inhibitory effect of E2F5 silencing.\",\n      \"method\": \"siRNA knockdown, CyclinE overexpression rescue, pharmacological Wnt pathway modulation (BML-284), in vivo DAS mouse model, Western blot\",\n      \"journal\": \"Diabetes & metabolism journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — pharmacological epistasis plus genetic rescue in vitro and in vivo, single lab\",\n      \"pmids\": [\"40890020\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"E2F5 is a transcriptional regulator that forms heterodimers with DP proteins and associates preferentially with the pocket protein p130 (not pRb) to mediate G1 arrest; it shuttles between cytoplasm and nucleus via CRM1-mediated export and an N-terminal import signal, with nuclear entry driven by differentiation cues; while classically considered a repressor, E2F5 can function as a transcriptional activator (e.g., at MMP-2/MMP-9, dmc1, MYCN, and HPV18 E6/E7 promoters) through context-dependent complex formation (e.g., E2F5-TFDP1-BRG1); its stability is regulated post-transcriptionally by m6A methylation via METTL3 and by the RNA-binding protein IMP3; in vivo loss-of-function studies reveal non-proliferative roles in choroid plexus secretory function, multiciliated cell differentiation, spermatogenesis (via dmc1 transactivation), and mammary alveolar development, while acting as a tumor suppressor in mammary tissue whose loss eventually drives metastatic tumors.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"E2F5 is a DP-heterodimerizing transcription factor of the E2F family that, with E2F4, defines a structurally and functionally distinct subfamily and serves as the principal effector of pocket-protein-mediated transcriptional control [#0, #1]. It heterodimerizes with DP-1 for high-affinity binding to E2F DNA sites and associates preferentially with the pocket protein p130 rather than pRb or p107 [#0, #2]; this p130 association is required for E2F5's repressive activity in vivo, since E2F5 alone cannot oppose activator E2Fs but does so when co-expressed with p130 [#9]. Genetic ablation shows E2F5 is dispensable for normal cell-cycle progression but, redundantly with E2F4, is necessary for p16INK4a/pocket-protein-driven G1 arrest [#4]. Beyond proliferative control, E2F5 has prominent roles in terminal differentiation and secretory tissue function: its loss causes choroid plexus secretory dysfunction and hydrocephalus [#3], impairs multiciliated cell development in efferent ducts and kidney [#14, #15], and is required for meiotic recombination during spermatogenesis through direct transactivation of dmc1 [#19]. In mammary epithelium E2F5 promotes alveolar progenitor differentiation and acts as a tumor suppressor whose loss, after latency, yields metastatic tumors, with chromatin effects manifest as altered H3K27me3 at luminal progenitor genes [#26]. Although classically a repressor, E2F5 functions context-dependently as a transcriptional activator at the HPV18 E6/E7, MYCN, MMP-2/MMP-9, and dmc1 promoters, in the MYCN case through an E2F5-TFDP1-BRG1 complex that deposits activating histone marks [#10, #16, #18, #22]. E2F5 subcellular distribution is dynamically regulated: nuclear import depends on its N-terminal 56 residues independent of DP/pRb, CRM1 mediates its nuclear export, and differentiation cues drive its nuclear translocation [#6]. Its abundance is controlled post-transcriptionally by METTL3-dependent m6A methylation and by the RNA-binding protein IMP3, both stabilizing E2F5 mRNA [#24, #25].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that E2F5 is a bona fide E2F-family member required showing it could engage E2F DNA elements and pocket proteins; cloning revealed DP-1 heterodimerization, high-affinity DNA binding, and selective p130 association distinguishing it from pRb-binding activator E2Fs.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation and DNA-binding assays after cloning\",\n      \"pmids\": [\"7892279\", \"7760804\", \"7542760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the in vivo target gene repertoire\", \"Functional consequence of p130 selectivity not yet tested\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Whether E2F5 was an activator or repressor was resolved by mapping a C-terminal activation domain that is inactivated upon pocket-protein binding, placing E2F4/E2F5 in a distinct functional subfamily.\",\n      \"evidence\": \"Reporter assays in yeast and mammalian cells with deletion mutagenesis\",\n      \"pmids\": [\"7542760\", \"9464260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish which mode dominates at endogenous promoters\", \"Co-regulators of activation/repression not identified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"The physiological non-proliferative role was first revealed when E2F5 knockout mice developed hydrocephalus from choroid plexus secretory dysfunction without cell-cycle defects, decoupling E2F5 from canonical proliferation control.\",\n      \"evidence\": \"Homozygous knockout mice with histology, EM, and in situ hybridization\",\n      \"pmids\": [\"9553039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Secretory target genes in choroid plexus not identified\", \"Mechanism linking E2F5 to fluid production unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Genetic redundancy with E2F4 was defined by double-knockout neonatal lethality and the failure of double-null fibroblasts to arrest in response to p16INK4a, establishing E2F4/E2F5 as the required effectors of pocket-protein G1 arrest while being dispensable for proliferation per se.\",\n      \"evidence\": \"E2F4/E2F5 double-knockout mouse genetics and p16INK4a-induced arrest assays\",\n      \"pmids\": [\"11030352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve E2F4 vs E2F5 individual contributions to arrest\", \"Target genes mediating arrest not enumerated\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"An oncogenic capacity was demonstrated by E2F5 cooperating with DP1 and activated RAS to transform primary kidney cells, hinting at a context where E2F5 drives rather than restrains growth.\",\n      \"evidence\": \"Focus-formation assay in primary BRK cells with gene mapping\",\n      \"pmids\": [\"10738311\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transformation in an artificial overexpression context\", \"Did not identify transformation-relevant target genes\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The basis for E2F5's regulated localization was established by mapping an N-terminal import signal independent of DP/pRb and a CRM1-dependent export region, with differentiation driving nuclear entry.\",\n      \"evidence\": \"In vitro nuclear import in permeabilized cells, leptomycin B inhibition, and deletion mutagenesis with keratinocyte immunofluorescence\",\n      \"pmids\": [\"12089160\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Import receptor not identified\", \"Signal triggering differentiation-induced translocation unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The requirement of p130 for repressive function in vivo was confirmed by showing E2F5 alone cannot block activator-E2F-driven proliferation in lens, but does so when co-expressed with p130.\",\n      \"evidence\": \"Transgenic mouse crosses with BrdU incorporation and immunohistochemistry\",\n      \"pmids\": [\"18385796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test endogenous p130 dependence\", \"Repressed target genes not catalogued\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The classical repressor view was challenged by identifying E2F5 as a direct activator of HPV18 E6/E7 oncogenes that promotes S-phase entry in HPV18-positive cells, establishing context-dependent activation.\",\n      \"evidence\": \"Sequential siRNA silencing of E2F members with luciferase reporters and cell-cycle analysis\",\n      \"pmids\": [\"20639900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cofactors converting E2F5 to activator not defined\", \"Specificity for HPV18 vs cellular promoters unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Post-transcriptional control of E2F5 repressor activity was linked to disease by showing mutant-p53-induced miR-128-2 targets E2F5, relieving its repression of p21 and driving chemoresistance.\",\n      \"evidence\": \"Reporter assays, miRNA overexpression/knockdown and ChIP in NSCLC cells\",\n      \"pmids\": [\"22193543\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct E2F5 binding at p21 promoter not shown in this study\", \"Generality beyond NSCLC unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Direct promoter targets in differentiation were defined by ChIP showing E2F5 represses the differentiation inhibitors ID1 and HMOX1 downstream of miR-98 to control myogenesis.\",\n      \"evidence\": \"Transcriptomics, miRNA target validation, ChIP, and double-knockdown epistasis in myoblasts\",\n      \"pmids\": [\"25422988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactor requirements at these promoters not defined\", \"Whether repression requires p130 not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Tissue-specific developmental roles in ciliogenesis were established by conditional E2f4/E2f5 deletion eliminating multiciliated and absorptive cells in efferent ducts, causing male sterility from defective fluid absorption.\",\n      \"evidence\": \"Conditional knockout mouse genetics with histology and immunohistochemistry\",\n      \"pmids\": [\"26825228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ciliogenesis target genes not identified\", \"Division of labor between E2F4 and E2F5 unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A proliferative signaling axis was proposed in prostate cancer wherein E2F5 acts with p38 to drive linker-region SMAD3 phosphorylation, with co-knockdown causing G1 arrest.\",\n      \"evidence\": \"siRNA knockdown with Western blot and cell-cycle analysis in PC3 cells and patient tissue\",\n      \"pmids\": [\"26919443\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets of the axis not defined\", \"Whether E2F5 regulates p38 directly unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Species-specific dominance within the subfamily was revealed in zebrafish where E2f5, not E2f4, is the essential factor for multiciliated cell development in kidney tubules.\",\n      \"evidence\": \"Zebrafish mutant and double-mutant genetics with whole-mount immunostaining\",\n      \"pmids\": [\"30218642\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for E2f4/E2f5 functional swap between species unknown\", \"Ciliogenesis targets not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"E2F5 was embedded in oncogenic transcriptional circuits by showing MYCN directly induces E2F5, and E2F5 knockdown reduces CDK2/CDK6 and proliferation in MYCN-amplified neuroblastoma.\",\n      \"evidence\": \"ChIP, luciferase reporter, siRNA knockdown and Western blot\",\n      \"pmids\": [\"30765227\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether E2F5 directly activates CDK2/CDK6 not shown\", \"Feedback onto MYCN not addressed here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"E2F5 was shown to act as a transcriptional activator in a feed-forward differentiation circuit by binding the lncPCAT1 promoter to drive BMP2 and osteogenic differentiation in periodontal stem cells.\",\n      \"evidence\": \"ChIP, luciferase reporter, miRNA sponge validation and differentiation assays\",\n      \"pmids\": [\"30997692\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cofactors enabling activation not defined\", \"Generality across stem cell types unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Direct activator/repressor duality at metastasis genes was demonstrated by ChIP showing E2F5 represses TFPI2 while activating MMP-2/MMP-9 to promote prostate cancer invasion.\",\n      \"evidence\": \"ChIP-qPCR with site-directed mutagenesis, reporter assays, zymography and Co-IP in tissue\",\n      \"pmids\": [\"32386317\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of activation vs repression at the same factor not defined\", \"Partner proteins at these promoters not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The in vivo developmental and meiotic program was defined by zebrafish showing E2F5 directly transactivates dmc1 to enable meiotic recombination during spermatogenesis, with dmc1 overexpression rescuing fertility, plus jagged2b activation regulating multiciliated cell fate.\",\n      \"evidence\": \"Zebrafish mutant genetics, transcriptomics, ChIP on dmc1, and dmc1 rescue with e2f5;tp53 double mutants\",\n      \"pmids\": [\"32196499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors enabling dmc1 activation not identified\", \"Conservation of dmc1 regulation in mammals not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"An anti-apoptotic role was established by showing E2F5 knockdown induces TP53-target pro-apoptotic genes only in wild-type-TP53 breast cancer cells, defining a TP53-dependent suppression of apoptosis.\",\n      \"evidence\": \"siRNA knockdown with TP53 co-silencing epistasis and cell-death assays in MCF7\",\n      \"pmids\": [\"33000282\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking E2F5 to TP53 target repression not defined\", \"Direct binding at BAX/NOXA/PUMA promoters not shown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A physical partner and feedback loop driving E2F5 abundance were identified: CDK13 binds E2F5 and a circCDK13/miR-212-5p/449a axis relieves E2F5 repression to amplify proliferation.\",\n      \"evidence\": \"Co-IP/mass spectrometry, CRISPR endogenous activation and gain/loss-of-function in vitro and in vivo\",\n      \"pmids\": [\"33390186\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of direct CDK13-E2F5 binding (e.g., phosphorylation) not defined\", \"Reciprocal validation of the interaction limited\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The mechanism of context-dependent activation was advanced by showing an E2F5-TFDP1-BRG1 complex binds the MYCN promoter and deposits H3 acetylation and H3K4me3 to recruit RNA Pol II during liver regeneration.\",\n      \"evidence\": \"RNAi, ChIP for BRG1/E2F5/TFDP1, histone modification analysis and MYCN rescue in BRG1-null hepatocytes\",\n      \"pmids\": [\"34746136\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the same complex operates at other activated promoters not tested\", \"Direct E2F5-BRG1 contact not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"E2F5 was linked to gastric cancer growth by transcriptional upregulation of UBE2T, with UBE2T rescue reversing the phenotype of E2F5 depletion.\",\n      \"evidence\": \"siRNA knockdown, GSEA, transcription regulation assay and UBE2T rescue\",\n      \"pmids\": [\"34583905\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No ChIP confirming direct UBE2T promoter binding\", \"Single lab without mechanistic characterization\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Post-transcriptional stabilization of E2F5 was defined by demonstrating METTL3-dependent m6A methylation increases E2F5 mRNA stability, with E2F5 overexpression rescuing the anti-tumor effect of METTL3 loss in pancreatic cancer.\",\n      \"evidence\": \"MeRIP assay, RT-qPCR, Western blot and rescue experiments\",\n      \"pmids\": [\"35985439\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"m6A reader mediating stabilization not identified\", \"Site-level m6A mapping on E2F5 not shown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A second RNA-based stability mechanism was established by showing IMP3 directly binds E2F5 mRNA and prolongs its half-life, supporting OSCC proliferation.\",\n      \"evidence\": \"RNA immunoprecipitation, mRNA stability assay, siRNA knockdown and xenograft\",\n      \"pmids\": [\"38271139\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relationship between IMP3 and METTL3 m6A regulation not addressed\", \"Binding site on E2F5 mRNA not mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The mammary tumor-suppressor and differentiation role was defined by conditional knockout showing E2F5 promotes alveolar progenitor differentiation via H3K27me3 control at luminal progenitor genes, with loss eventually producing metastatic tumors.\",\n      \"evidence\": \"Mammary-specific conditional knockout with scRNAseq, H3K27me3 chromatin profiling, RNAseq, WGS and transplantation\",\n      \"pmids\": [\"39341991\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting E2F5 to H3K27me3 deposition unknown\", \"Driver events of late metastatic tumors not fully resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A vascular disease role was added by showing E2F5 promotes VSMC phenotypic switching in diabetic atherosclerosis through Wnt/β-catenin activation, with CyclinE rescuing E2F5 silencing.\",\n      \"evidence\": \"siRNA knockdown, CyclinE rescue, pharmacological Wnt modulation and in vivo DAS mouse model\",\n      \"pmids\": [\"40890020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct E2F5 targets in the Wnt axis not identified\", \"Whether E2F5 acts upstream or parallel to Wnt unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved what molecular switch converts E2F5 between p130-dependent repression and BRG1/cofactor-dependent activation at individual promoters, and how its differentiation, tumor-suppressor, and oncogenic roles are selected in a given tissue.\",\n      \"evidence\": \"No timeline study defines a unifying determinant of the activator-repressor switch across contexts\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No general rule for activation vs repression specificity\", \"Tissue-context determinants of tumor-suppressor vs oncogenic output unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 9, 10, 18, 19, 22]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 18, 19]},\n      {\"term_id\": \"GO:0140297\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 7, 8]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [18, 19, 26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4, 9]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 18, 19, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 14, 15, 19, 26]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [22, 26]}\n    ],\n    \"complexes\": [\n      \"E2F5-DP1 heterodimer\",\n      \"E2F5-p130 repressor complex\",\n      \"E2F5-TFDP1-BRG1 complex\"\n    ],\n    \"partners\": [\n      \"TFDP1\",\n      \"RBL2\",\n      \"BRG1\",\n      \"CDK13\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":8,"faith_pct":87.5}}